Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2017 Apr 7;7:46195. doi: 10.1038/srep46195

Klotho preservation via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice

Wenjun Lin 1, Yanning Li 2, Fang chen 2, Shasha Yin 2, Zhihong Liu 1,a, Wangsen Cao 1,2,b
PMCID: PMC5384196  PMID: 28387374

Abstract

Bone loss and increased fracture are the devastating outcomes of chronic kidney disease-mineral and bone disorder (CKD-MBD) resulting from Klotho deficit-related mineral disturbance and hyperparathyroidism. Because Klotho down-regulation after renal injury is presumably affected by aberrant histone deacetylase (HDAC) activities, here we assess whether HDAC inhibition prevents Klotho loss and attenuates the CKD-associated bone complication in a mouse model of CKD-MBD. Mice fed adenine-containing diet developed the expected renal damage, a substantial Klotho loss and the deregulated key factors causally affecting bone remodeling, which were accompanied by a marked reduction of bone mineral density. Intriguingly, administration of a potent HDAC inhibitor trichostatin A (TSA) impressively alleviated the Klotho deficit and the observed alterations of serum, kidney and bone. TSA prevented Klotho loss by increasing the promoter-associated histone acetylation, therefore increasing Klotho transcription. More importantly the mice lacking Klotho by siRNA interference largely abolished the TSA protections against the serum and renal abnormalities, and the deranged bone micro-architectures. Thus, our study identified Klotho loss as a key event linking HDAC deregulation to the renal and bone injuries in CKD-MBD mice and demonstrated the therapeutic potentials of endogenous Klotho restoration by HDAC inhibition in treating CKD and the associated extrarenal complications.

Renal osteodystrophy and subsequent bone fracture are common complications of chronic kidney diseases (CKD), now classified as CKD-mineral and bone disorder (CKD-MBD)1, which is characterized by severe renal injury, disturbed mineral and hormone metabolisms accompanied by cardiovascular and bone complications. The low glomerular filtration rate associated with early CKD development retains excessive phosphorus that causes progressive rise of osteocyte-derived fibroblast growth factor-23 (FGF23) and parathyroid hormone (PTH) production, which adversely affect bone remodeling and resorption eventually ensuring osteoporotic bone complications2. The medications aiming at minimizing phosphorus retention through dietary therapy or alternative vitamin D supplementation improved the abnormal metabolism of minerals and hormones3. On the other hand, novel strategies modulating endogenous renal protective proteins might provide additional protections against the pathological processes. Recently a newly identified renal protein Klotho is found to be a key regulator of mineral metabolisms and kidney homeostasis4,5 and a potential target for treating the renal and bone injuries of CKD-MBD.

Klotho was originally identified as an antiaging protein highly expressed in renal tubule epithelial cells4,6. Mice lacking Klotho display accelerated aging phenotypes and the renal and extrarenal manifestations resembling patients with CKD-MBD7. In addition, the mice showed the low bone formation and resorption activities8,9, suggesting that Klotho can directly affect bone remodeling. Klotho is a membrane protein mainly functioning as a cofactor for FGF23 (fibroblast growth factor −23)10, through which it regulates phosphate and vitamin D metabolisms controlling the mineral levels in the body. A soluble form of Klotho, generated by differential splicing or ectodomain cleavage from the membrane-bound Klotho and released into blood, cerebral fluid and urine, possesses β-glucuronidase activity and regulates various cell receptors and ion transporters critically protecting kidney and bone functions11,12,13. Klotho is sensitive to various acute or chronic renal injuries and declined early in renal patients and experimental animals of CKD14,15, whereas transgenic Klotho over-expression, exogenous Klotho supplementation or the maintaining Klotho via re-activating endogenous Klotho protects against the renal damage and functional loss in CKD animals16,17,18, suggesting that Klotho is a remarkable renal protector with therapeutic potentials. Klotho suppression after renal injury reportedly involves transcription factor-mediated transcriptional repression and epigenetic DNA or protein modifications19,20 among them deregulated histone deacetylase (HDAC) activities seem to be an important but less explored mechanism that promotes the pathological Klotho down-regulation.

Protein acetylation modifications of histone or non-histone proteins, catalyzed by two groups of enzymes of opposite functions - histone acetyl-transferase and HDAC, are emerging as fundamental mechanisms controlling renal physiology and pathogenesis21,22,23,24. Aberrant HDAC activities are associated with various acute or chronic kidney diseases such as diabetic nephropathy, CKD and polycystic kidney disease in animal studies, in which HADC inhibition significantly delayed the pathological processes25,26,27,28,29, but the underlying molecular mechanisms and the key effecter genes involved are incompletely understood. Recent studies reported that Klotho suppression after acute kidney injury involved the HDAC1/2-associated pro-inflammatory signaling20 and Klotho repressions incurred by the promoter hypermethylation in patients and animal studies of CKD30,31 are presumably mediated by a transcription repression mechanism requiring HDAC activities, raising the possibility that inhibition of HDAC might relieve Klotho repression and restore its renal protective capacities.

In this study we seek to investigate whether HDAC inhibition prevents Klotho suppression and its functional significances in a mouse model of adenine-induced CKD-MBD. Our study will clarify whether Klotho is a key gene involved in the HDAC aberration-associated renal and bone injuries and bring new insights into the Klotho-targeted therapies in treating CKD and the related extrarenal complications.

Results

HDAC inhibition prevents CKD-associated renal and bone damage in adenine-fed mice

To gain insights into the therapeutic efficacy of HDAC inhibition on CKD-associated bone complication, we established an adenine-fed mouse model of CKD-MBD32,33,34. We divided mice into control, TSA, adenine, and TSA-treated adenine groups and found that the kidneys from adenine mice fed 6 weeks developed extensive renal pathological changes such as renal tubular atrophy and interstitial fibrosis (Fig. 1A upper panel and Fig. 1B). In addition, adenine mice had marked increases of blood urine nitrogen (BUN) and creatinine (Fig. 1C) - two major parameters indicating the low glomerular infiltration rate due to renal functional loss. The histological examination of adenine mice revealed the marked osteoporosis-like changes on distal femurs - the thinner and deranged trabeculae with increased lacuna (Fig. 1A, the white arrow heads in lower panel). The X-ray scanning showed the marked loss of bone mineral density (BMD) at the distal femurs (Fig. 1D,E). Impressively, TSA (trichostatin A), a potent general HDAC inhibitor frequently used in HDAC inhibition study, effectively reduced the renal tubule damage and fibrosis lesions, attenuated the increased BUN and creatinine, and significantly improved the bone pathological changes and BMD loss (Fig. 1A–E). These results clearly demonstrate that HDAC inhibition protects against the renal and bone injuries in adenine mice.

Figure 1. HDAC inhibition prevents CKD-associated renal and bone damage in adenine-fed mice.

Figure 1

Open in a new tab

(A) Representative Masson’s trichrome staining of kidney sections and H&E stained femur sections from control, TSA, adenine and TSA-treated adenine mice (n = 6 in each group, 6 weeks). (B) Semi-quantifications of renal interstitial fibrosis (the percentage of blue-colored cortex area over the whole cortex field from Masson’s trichrome-stained sections) from all mice. (C) Average levels of serum blood urea nitrogen (BUN) and Creatinine (Cre). The quantifications were based on all mice tested. (D) Representative femur radiographs from Control, TSA, adenine and TSA-treated adenine mice. The lower panels are the enlarged views of framed images above (E) Quantifications of bone density of Fig. 1D from all mice. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 versus control; #P < 0.05, ##P < 0.01 versus adenine mice.

HDAC inhibition attenuates the CKD-associated abnormalities of mineral, hormone and osteogenic markers

To gain further insight into the molecular basis of TSA protection of CKD-associated bone injury, we examined a number of key factors and osteogenic markers closely related to bone remodeling. Adenine mice displayed elevated serum phosphate, intact parathyroid hormone (iPTH) and FGF23, and decreased 1,25-dihydroxyvitamin D3 (1,25 (OH)2D3) (Fig. 2A) - the characteristic serological changes of CKD-MBD that causally related to bone damage. Bone morphogenesis protein-7 (BMP-7) is a kidney-enriched protein released into circulation and beneficially regulates renal function and bone remodeling, which is significantly reduced; while the phosphorylated Smad3, the active form of Smad3 mediating transforming growth factor-beta (TGFβ) signaling leading to myofibroblast trans-differentiation and extra cellular matrix protein expression, is dramatically induced in adenine mouse kidney (Fig. 2B,C). In addition, the femurs of adenine mice expressed reduced Runx2 (runt-related transcription factor 2) - a transcription factor critical for osteoblast differentiation and Spp1 (Secreted phosphoprotein 1) - an extracellular matrix protein essential for bone mass maintenance (Fig. 2D). Intriguingly TSA treatment significantly mitigated all these abnormalities, indicating that HDAC inhibition improves renal function and beneficially affects the CKD-associated bone remodeling.

Figure 2. HDAC inhibition attenuates CKD-associated abnormalities of mineral, hormone and bone remodeling-related gene expression.

Figure 2

Open in a new tab

(A) Average concentrations of serum phosphorus (P), intact parathyroid hormone (iPTH), FGF23 and 1,25-dihydroxyvitamin D3 (1,25 (OH)2D3 from Control, TSA, adenine and TSA-treated adenine mice of 6 weeks (n = 6). (B) Renal BMP-7 and phosphorylated Smad3 (P-Smad3) were examined from all mice by Western blotting (two randomly selected samples from each group were shown). Beta-actin (β-actin) served as loading control. (C) Quantifications of Figure 2B (n = 6 in each group). (D) Average levels of bone Runx2 and Spp1 mRNA examined by qRT-PCT (n = 6). The data are presented as mean ± SD. *P < 0.05, **P < 0.01 versus control; #P < 0.05 versus adenine mice.

HDAC inhibition up-regulates renal Klotho

Klotho is a key gene profoundly affecting mineral metabolism and bone remodeling, but reportedly suppressed after renal injury. We then decided to test whether HDAC inhibition affects Klotho expression. The results showed that Klotho levels in kidney, blood circulation and femur were all markedly reduced in adenine mice, as demonstrated by immunohistochemical and Western blotting examinations of kidney tissues (Fig. 3A,D and E), ELISA assay of mouse sera (Fig. 3B) and quantitative real time PCR measurement of mRNA in femur. (Fig. 3C). However TSA treatment impressively attenuated the Klotho reductions in all assays. In addition, the typical CKD-associated pathological alterations, such as the reduction of E-cadherin- an epithelial cell marker and the induction of α-SMA, the myofibroblast differentiation marker, were also attenuated by TSA treatment, indicating that HDAC inhibition effectively prevents Klotho loss, which might account for the renal and bone protections.

Figure 3. HDAC inhibition restores declined renal Klotho in adenine mice.

Figure 3

Open in a new tab

(A) Immunohistochemical staining. The kidney sections from control, TSA, adenine and TSA-treated adenine mice (6 weeks, n = 6) were examined by immunohistochemical staining for renal Klotho expression. The representative figures from each group were shown. (B) Serum Klotho levels. The average concentrations of serum Klotho from control, TSA, adenine and TSA-treated adenine mice were measured by ELISA (n = 6). (C) Bone Klotho mRNA. The relative levels of Klotho mRNA were examined from control, TSA, adenine and TSA-treated adenine mouse femurs by qRT-PCR (n = 6). (D) Renal expressions of Klotho, α-SMA and E-cadherin were assayed by Western blotting from the mouse kidneys (2 randomly selected samples were shown). (E) Quantifications of Fig. 3D (n = 6). Data are presented as mean ± SD. *P < 0.05 versus control, #P < 0.05 versus adenine mice.

HDAC inhibition up-regulates Klotho via reversing the promoter hypoacetylation and increasing Klotho transcription

We next decided to further determine the epigenetic mechanism of Klotho up-regulation by HDAC inhibition. We found that TSA treatment increased the basal Klotho protein abundance in mouse kidney (Fig. 4A and B) and time- and dose-dependently increased Klotho protein levels in renal tubule HK2 cells (Fig. 4C). In order to ensure that Klotho up-regulation by TSA is indeed caused by HDAC inhibition, we also tested another general HDAC inhibitor SAHA (suberoylanilide hydroxamic acid) and found that SAHA also dose-dependently increase Klotho expression (Fig. 4C, right panel). To clarify whether TSA up-regulation of Klotho occurs at the gene transcription level, we transfected cells with a luciferase reporter plasmid containing 2 kb of mouse Klotho promoter and found that TSA dose-dependently increased the luciferase activities, thus, increasing the Klotho promoter transcription (Fig. 4D). Consistently, adenine mouse kidney exhibited reduced Klotho mRNA, but TSA treatment inhibited the reduction (Fig. 4E). Further we examined the histone acetylation status around Klotho promoter by ChIP (chromatin immunoprecipitation) assay. We precipitated the protein-cross-linked genomic DNA with a specific antibody to acetylated histone3, and then measured the amount of DNA associated with acetylated histone 3 by PCR using a primer set specific for Klotho promoter. The results showed that adenine mouse kidney displayed hypoacetylated histone3 on Klotho promoter, which is significantly alleviated by TSA treatment (Fig. 4F and G). Taken together these results suggest that HDAC inhibition recovered the Klotho suppression in adenine mouse kidney by increasing Klotho promoter acetylation and its transcription.

Figure 4. HDAC inhibition up-regulates Klotho via reversing the promoter hypoacetylation and increasing Klotho transcription.

Figure 4

Open in a new tab

(A) TSA up-regulates Klotho in kidney. Kidney lysates from control and TSA-treated mice (6 weeks) were analyzed for Klotho protein levels by Western blotting (3 randomly selected samples from each group were shown). (B) Quantification of Fig. 3A. (C) HDAC inhibition dose and time-dependent up-regulation of Klotho in renal cells. HK2 cells were treated TSA of various doses (10, 30, or 100 ng/ml) or different times (100 ng/ml for 8, 16, and 24 h), or treated with SAHA of various amounts (1, 2, 5 and 10 μM) for 24 h, and then cell lysates were analyzed for Klotho protein expression by Western blotting. (D) Luciferase assay. HK2 cells were transfected with a mouse Klotho promoter reporter (mKLp-Luc) plus a renilla luciferase plasmid control for 20 h, and then TSA of two doses (10 and 100 ng/ml) was added to the cells for additional 24 h. The cell lysates were analyzed for luciferase activities, presented as the fold changes of the reporter luciferase activities divided by that of renilla control. (E) Klotho mRNA from mouse kidney. The average levels of Klotho mRNA from control (Con), TSA, adenine (Ad) and TSA-treated adenine mice (6 weeks, n = 6) were determined by qRT-PCR. (F) ChIP assay. Mouse kidney lysates from control, TSA, adenine and TSA-treated adenine mice were cross-linked and immune-precipitated with an anti-acetylated Histone3 antibody. The immune-precipitated DNAs were further PCR-amplified with primer sets specific for mouse Klotho promoter (KLpro). The genomic DNAs served as input control. The PCR products were analyzed on a 1.5% agarose gel and visualized under UC light. Representative results were shown. (G) Semi-quantification of Fig. 4F from all mice (n = 6 in each group). Data are presented as mean ± SD. Cell-bases assays were repeated three times and the representative results were shown. *P < 0.05 versus control; #P < 0.05 versus adenine.

Klotho is critical for the renal protection by HDAC inhibition

To determine the functional significance of Klotho restoration in the renal and bone protections by HDAC inhibition, we tested the effects of Klotho knockdown on the improved key factors and osteogenic markers related to bone injury by HDAC inhibition. We divided mice into two groups injected with either siRNA control or siRNA Klotho that effectively reduced renal Klotho (Fig. 5A) and then subjected mice to TSA and/or adenine treatment as before. The results showed that siRNA Klotho-treated mice displayed slight increase of renal fibrosis (Fig. 5B and C), phosphorylated Smad3 and reduced BMP-7 (Fig. 5D and E). Further, adenine feeding enhanced the alterations. Intriguingly, while TSA treatment reduced the renal damage and fibrosis and improved phosphorylated Smad3 and BMP-7 in siRNA control-injected mice, the protective effects were significantly reduced in siRNA Klotho-injected mice (Fig. 5A–E). Similarly TSA improvements of the increased serum phosphorus, iPTH and FGF23 were also significantly abrogated in siRNA-Klotho mice (Fig. 5F), indicating that Klotho critically mediated the renal protection by HDAC inhibition. We also measured serum calcium levels and found no significant changes among groups.

Figure 5. Klotho is critical for the renal protection by HDAC inhibition.

Figure 5

Open in a new tab

Mice receiving siRNA-control or siRNA-Klotho underwent TSA, adenine or TSA plus adenine treatments for 6 weeks (n = 6 in each group). (A) Renal Klotho protein levels from siRNA-control or siRNA-Klotho-injected mice were examined (6 weeks, three randomly selected samples from each group were shown) by Western blotting. (B) Representative Masson’s trichrome staining of kidney sections from siRNA-control or siRNA-Klotho-injected control, TSA, adenine and TSA-treated adenine mice (6 weeks, n = 6 in each group). (C) Quantifications of renal interstitial fibrosis (the percentage of blue-colored cortex area over the whole cortex field from Masson’s trichrome-stained sections) from all mice in Fig. 5B. (D) Renal expressions of BMP-7 and phosphorylated Smad3 were examined by Western blotting (Two randomly selected samples were shown). (E) Quantifications of BMP-7 and P-Smad3 in Fig. 5D (n = 6). (F) Average serum levels of phosphorus (P), iPTH, FGF23 and Calcium (Ca), from all mice (n = 6). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 versus control, #P < 0.05, ##P < 0.01 versus adenine treatment in siR-control mice; ΔP < 0.05, ΔΔP < 0.01 versus control in siR-Klotho mice.

Klotho is essential for the bone protection by HDAC inhibition

We further examined the distal femur by H&E staining and found that TSA treatment reduced the thinner and deranged trabeculae and the enlarged bone marrow cavity in siRNA control-injected adenine mice, but lack of Klotho by siRNA interference largely eliminated the protective effects (Fig. 6A). In addition, TSA attenuation of decreased Runx2 and Spp1 was also diminished in siRNA-Klotho mice (Fig. 6B). To better quantitatively determine the changes of bone structures, we examined the femur micro-architectures by micro-CT (computed tomography) 3D analysis. The results showed that adenine mice displayed the typical osteoporotic changes such as less trabecular bone volume versus tissue volume (BV/TV), reduced trabecular bone number (Tb.N) and trabecular thickness (Tb,Th), and increased trabecular bone separation (Tb.Sp) (comparing column 1 and 3 in Fig. 6C and lane 1/4 and 3/7 in Fig. 6D) in siRNA control-injected mice, whereas TSA treatment significantly inhibited these alterations (comparing column/lane 4 and 3 upper panel in Fig. 6C and D). However the protective effects were largely abolished in siRNA-Klotho-injected mice (comparing column 4 and 3 lower panel in Fig. 6C and lane 8 and 7 in Fig. 6D). Altogether these results strongly indicate that Klotho plays a critical role in the bone protection by HDAC inhibition in CKD-MBD mice.

Figure 6. Klotho is essential for the bone protection by HDAC inhibition.

Figure 6

Open in a new tab

(A) Representative H&E staining of mouse distal femur sections from siRNA-control or siRNA-Klotho-injected control, TSA, adenine and TSA-treated adenine mice (6 weeks, n = 6 in each group). (B) Average bone mRNA levels of Runx2 and Spp1 examined by qRT-PCR (n = 6). (C) Representative micro-CT 3D images of trabecular architectures of the distal femurs from mice as in Fig. 6A. (D) Quantitative analyses of the ratio of bone volume to tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp) from micro-CT examinations (n = 6). Data are presented as the mean ± SD. *P < 0.05, **P < 0.01 versus control, #P < 0.05, ##P < 0.01 versus adenine treatment in siR-control mice; ΔP < 0.05, ΔΔP < 0.01 versus control in siR-Klotho mice.

Discussion

In this study we aimed to explore the potentials of Klotho restoration by epigenetic HDAC inhibition and its functional relevance to the renal and bone protections in a mouse model of CKD-MBD. We found that HDAC inhibitor TSA effectively reduced renal injury with the impressive Klotho restoration, improved the deregulated key factors involved in bone remodeling and attenuated the associated bone damage. We further demonstrated that HDAC inhibition prevented Klotho loss by increasing the promoter acetylation and its transcription. Finally we showed that the Klotho restoration by HDAC inhibition plays a critical role for the renal and bone because the protective effects were significantly reduced in mice lacking Klotho. Thus the results from our study revealed a key target and the mode of action of the kidney and bone protections by HDAC inhibition.

Adenine mouse model was initially established in rat for studying chronic renal failure and turned out to be a good model of CKD-MBD32,34,35. Adenine is readily converted to 2, 8-dihydroxyadenine in kidney, forming insoluble crystals that block renal tubules and subsequently causing extensive renal tubule damage, disturbed mineral and hormone metabolisms and the consequential osteodystrophy32,36. In our study, adenine-fed mice for 6 weeks develop typical renal lesions of CKD with marked increase of serum phosphorus, iPTH and FGF23, 1, 25(OH)2D3 reduction and osteoporosis, except that calcium levels stayed normal as reported previously by others37. More importantly, the mice showed a drastic Klotho suppression in kidney and blood circulation. Thus adenine-fed mice are ideal for studying Klotho functions and its relevance to CKD pathogenesis with bone complications.

CKD development and progression are promoted by a variety of pathological processes of various etiologies38. Epigenetic modulations of renal protective or pathological protein expressions by DNA and protein methylation, protein acetylation or miRNA modification add additional controls over the processes. Aberrant HDAC activities are reportedly involved in various acute and chronic kidney diseases and affect many cellular pathological processes such as inflammation and renal fibrosis. In particular, HDAC1 and 2 are associated with TNFα-incurred acute kidney injury20; abnormal HDAC2 and HDAC4 mediate the pathogenesis of diabetic podocytopathy39,40 and HDAC1 and HDAC6 contribute to the progression of polycystic kidney disease41,42. HDAC inhibitions with general or selective HDAC inhibitor effectively improved the pathological changes in the animal studies. However many cell components mediate CKD pathogenesis and the key genes that confer the renal protection by HDAC inhibition are incompletely understood. Now our results provided clear evidence that HDAC inhibition-associated Klotho restoration improved the disturbed mineral and hormone metabolisms, attenuated the expression of CKD-associated proteins and reduced the renal and bone injuries in adenine mice, establishing Klotho as a critical target of HDAC inhibition in the renal and bone protections.

Klotho prevents the renal and bone damage in adenine mice essentially through interrupting pro-fibrotic signaling. As demonstrated in our previous33 and current studies that Klotho preservation by endogenous Klotho re-activation in adenine mice inhibited TGFβ- induced Smad signaling (Figs 2B and 5D), therefore reducing myofibroblast trans-differentiation and extra cellular matrix protein expressions. Klotho beneficial modulations of disturbed mineral and FGF23 metabolisms33 (Fig. 2 in this study) as well as its anti-inflammation43 and oxidative stress-balancing44 functions presumably provide additional protections. BMP-7 is another renal and bone protective protein and its down-regulation by aberrant HDAC activities worsen renal and bone pathogenesis45. BMP-7 plays pivotal roles promoting the proliferation and repair of the tubular cells after renal injury and beneficially affects bone remodeling by promoting osteoblast growth and differentiation46,47. Thus, BMP-7 recovery by HDAC inhibition in adenine mouse kidney as demonstrated in our study (Fig. 2B) also contributes to the renal and bone protections. Intriguingly, BMP-7 recovery by HDAC inhibition in adenine mouse kidney is causally affected by Klotho (Fig. 5), highlighting the essential role of Klotho restoration in the renal and bone protections by HDAC inhibition.

Bone undergoes continues remodeling balanced by two opposite processes - the osteoblast maturation-associated bone formation and the osteoclast-mediated bone resorption. It is reported that HDAC inhibition by TSA promotes osteoblast maturation in vitro, inhibits osteoclast differentiation of bone marrow cells48,49 and mitigated osteoporotic injuries in animal studies50. Interestingly, previous studies reported that bone expressed low levels of Klotho51,52 and we found that TSA also substantially recovered the Klotho loss in adenine mouse femurs, which likely exerting a local protective effects. Still, kidney is the principal organ mediating Klotho effects53 because mice with systemic or nephron-specific Klotho knockout exhibit similar low bone formation activities and osteopenia8,17,53, suggesting that renal Klotho directly regulates the different stages of bone formation, remodeling and repair. In addition, some key minerals and hormones affected by Klotho such as calcium, phosphorus, FGF23 and PTH are essential for bone homeostasis5. Our results showed that HDAC inhibition by TSA not only effectively preserved Klotho, improved the CDK-associated protein expressions and reduced the renal pathogenesis in CKD-MBD mice, but also Klotho-sensitively normalized the key factors that causally affecting kidney and bone remodeling and consequently alleviated the kidney and bone damage, supporting that Klotho preservation contributes, at least in a significant part, to the kidney and bone protections by HDAC inhibition, which is consistent with previous study indicating that endogenous Klotho restoration by chemicals attenuated CKD-associated extrarenal complication of cardiovascular calcification18.

HDAC aberration-associated Klotho repression has been observed in TNFα-mediated NF-kB signaling in renal cells, in which HDAC1 and HDAC2 physically interact with NF-kB upon TNFα stimulation and presumably assist the transcriptional down-regulation of Klotho20; however this mode of action has not been verified in vivo. The promoter hypermethylation-mediated Klotho repressions are found in patients and animal models of CKD30,54. DNA methylation modification adds a methyl group to the cytosine residue within cytosine- phosphate-guanine (CpG) islands often located on gene’s enhancer or promoter55, which serves as a docking site for transcriptional repressor and HDAC to transcriptionally repress gene expression56,57, therefore requiring HDAC activities. Klotho promoter contains a large stretch of GC islands and binding sites for NF-kB20 and PPARγ58. We demonstrated that HDAC inhibition-associated Klotho preservation occurred at the transcription levels and Klotho promoter is associated with reduced acetylation of histone3 in adenine mouse kidney, but HDAC treatment effectively inhibited the reduction, suggesting that TAS preserved Klotho through a transcriptional up-regulation process. Epigenetic modifications of histone and DNA involve complicated and site-specific interplay with accessory mediators. Our results provide a molecular basis for the observed Klotho up-regulation by HADC inhibition and help explore the precise underlying mechanisms and the therapeutic designs.

In conclusion, the results from our study represent the first in vivo functional evaluation of the therapeutic efficacy of HDAC inhibition on Klotho restoration and CKD-MBD pathogenesis in mice. In addition, our results opened up new perspectives for the development of Klotho-targeted therapy in treating CKD and the associated extrarenal complications.

Materials and Methods

Animals and experimental design

Adenine model of CKD-MBD was established with C57BL/6 male mice of 8-weeks of age according to a previously-established protocol33. Mice were randomly divided into Control, TSA (SelleckChem, USA), Adenine (Sigma-Aldrich, USA) and TSA-treated Adenine groups (n = 6) and the experiments went for 6 weeks. Control mice were fed a standard powder diet containing 1.16% calcium, 0.73% phosphate, 18.2% protein, and 7.56 IU/g vitamin D3, (Collaboration BioMedical Inc., Nanjing, China); TSA mice received intraperitoneal injection of TSA (0.5 mg/kg body weight in 100 μl of PBS) daily; Adenine mice were fed the regular diet containing 0.2% adenine. At sacrifice, kidney, blood and femur were collected and stored at –80 °C until analysis. Use of animal and the experimental protocol were in accordance with the University Guidelines and approved by the Institutional Animal Care Committee (IACUC) of Nanjing University Medical School.

siRNA-mediated Klotho knockdown in mouse study

Mice were divided into two groups receiving siRNA-Klotho (targeting 5′-GCGACTACCCAGAGAGTAT-3′ in mouse Klotho gene)59 or a scrambled RNA 5′-CGUACGCGGAAUACUUCGA-3′ as control, respectively. Each mouse received 6 siRNA injections (10 nm in 200 μl of PBS) through tail vein once a week before and during adenine feeding for a total of 6 weeks. Both groups were subjected to TSA, adenine or TSA plus adenine treatment as above (n = 6 in each group).

Serum markers, histomorphological and histoimmunochemistry assay

Serum BUN, creatinine, calcium, and phosphorus were measured using a multichannel autoanalyzer (Hitachi 7180, Hitachi Ldt, Japan). Serum intact PTH (iPTH), FGF23 (C-terminal, Immutopics, USA), 1,25-dihydroxyvitamin D3 (1,25 (OH)2D3 (Immunodiagnostic Systems, UK) and Klotho (SEH757Mu, USCN Life Science Inc., China) were measured using enzyme-linked immunosorbent (ELISA) assay kits following manufacturers’ protocols.

Kidney tissue sections (3 μm) and femur sections (10 μm) were prepared by standard protocols and stained with either Mason’s trichrome staining or H&E (hematoxylin and eosin) method33,60. Immunohistochemistry was performed using anti-Klotho antibody. The images were obtained using a Nikon E800 microscope. The renal fibrosis was calculated as the ratio of collagen deposition in renal cortex (blue color area in Masson’s trichrome-stained sections) over the whole cortex area and semi-quantitatively measured from 10 randomly selected fields of each section of all experimental animals and analyzed by Image J software.

Bone mineral density and trabecular microstructure analyses

Bone mineral density (BMD) of femurs was measured with a Faxitron MX20 Specimen Radiography System (Faxitron X-ray Corp.,USA) and analyzed by Image J software. For trabecular micro-structure analysis, femurs were scanned with a micro-computed tomography scanner VivaCT80 (SCANCO Medical, Switzerland) at 15.6 μm voxel size, with 250 ms integration time, 55 kVp energy, and 145 μA intensity. A total of 100 slices from each sample were used to analyze the micro-architectures of trabeculae at the distal metaphyses, 78 μm from the growth plate. Three Dimensional (3D) images of trabeculae were acquired and the ratio of bone volume to tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and trabecular separation (Tb.Sp) were calculated.

Cell culture

Human proximal tubular epithelial cells (HK-2) were obtained from American Type Cell Culture (ATCC. USA), cultured in DMEM F-12 (Gibco, USA) medium supplemented with 10% fetal bovine serum (Gibco, USA) and maintained in a 5% CO2 incubator at 37 °C.

Klotho promoter reporter assay

The mouse Klotho promoter reporter plasmid containing 2 kb upstream of the transcription starting site (mKLp-Luc) constructed by PCR amplification of genomic DNA from mouse RAW cells in pGL3-basic vector has been described33. For luciferase assay, the reporter and a renilla luciferase control plasmids were co-transfected into HK2 cells with Lipofectamine 2000 reagents (Invitrogen, USA). Twenty four hours later, TSA was added for additional 24 hour and the cell lysates were collected and the luciferase activities were measured with a Luciferase Reporter Assay System (Promega, USA) in a GloMax luminometer. The relative luciferase activities were calculated as the ratio of luciferase activities of the reporter divided by the renilla activities.

Western blotting

Western blotting was performed with HK2 cells treated with various doses of TSA for different times, or with kidney tissue lysates essentially as before61. Aliquots of protein were subjected to sodium dodecylsulfate–polyacrylamide minigel electrophoresis and transferred to a Hybond-P membrane (GE Healthcare, Little Chalfont, UK), and then incubated with following primary and secondary antibodies: anti-Klotho (KO603, TransGenic, Japan), α-SMA (Abcam, MA, USA), E-cadherin (BD Transduction Laboratories, San Jose, USA), BMP-7 (Bioworld, USA), Phosphorylated Smad3 (Cell signaling Biotech, USA), acetyl-histone H3 (Millipore, Billerica, USA), β-actin, goat anti-rabbit IgG-HRP, and goat anti-mouse IgG-HRP (Yifeixue Biotech, Nanjing, China). Chromogenic detection was performed with ECL Western Blotting Detection Kit and quantified using Image J Software.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA from femur and kidney was extracted using TRI reagent (Sigma-Aldrich, USA).cDNA was synthesized from 2 mg of total RNA using a transcript first-strand cDNA synthesis Kit (Vazyme, China). The qRT-PCR reactions were performed in triplicate using the SYBR Green PCR Master Mix (Vazyme, China) with primer mKlothoF (5′-GATGGCAGAGAAATCAACACAGT-3′) and mKlothoR (5′-ACTACGTTCAAGTGGACACTACT-3′), Runx2 F: 5′-GACTGTGGTTACCGTCATG GC-3′; Runx2 R: 5′-ACTTGGTTTTTCATAACAGCGGA-3′; Spp1F: 5′-ATCTCAC CATTCGGATGAGTCT-3′; Spp1R: 5′-TGTAGGGACGATTGGAGTGAAA-3′.

Chromatin immunoprecipitation (ChIP)

Chromatin immunoprecipitation assay (ChIP) was carried out with a ChIP assay kit (Millipore, Billerica, MA) according to the manufacturer’s instructions. The Immunoprecipitation was performed with anti-acetyl histone H3 antibody (Millipore, Billerica, MA) or an isoform-matched IgG as control. Immunoprecipitated DNA was further PCR-amplified using primer set specific for mouse Klotho promoter mKLpF (5′-GCTGAGTTGTACCTTACTGAG-3′) and mKLpR (5′-CACCATATCCCGTTCATCAC-3′). PCR amplification profiles: 94 °C for 5 min followed by 94 °C 30 sec, 55 °C 1 min, 72 °C 1 min for a total of 30 cycles and a final 72 °C for 10 min. The PCR products were analyzed on 1.5% agarose gel and visualized under UC light.

Statistical analysis

Data are represented as mean ± standard deviation (SD). Statistical differences were assessed by Student’s t-test for comparisons of two groups, one-way analysis of variance (ANOVA) or ANOVA followed by Tukey’s post hoc test for comparisons of multiple groups. P < 0.05 and P < 0.01 were considered statistically significant and very significant.

Additional Information

How to cite this article: Lin, W. et al. Klotho restoration via histone deacetylase inhibition attenuates chronic kidney disease-associated bone injury in mice. Sci. Rep. 7, 46195; doi: 10.1038/srep46195 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgments

This work was supported by research grants from National Basic Research Program of China 973 Program (No.2012CB517606), National Nature Science Foundation of China (81470940 and 81670762), and the Major International (Regional) Joint Research Project (81320108007). We thank Dr. Jiang, Qing, the Center of Diagnosis and Treatment for Joint Disease, Nanjing Drum Tower Hospital Affiliated with Nanjing University School of Medicine, Nanjing, China, for his critical advice and support for the bone analysis.

Footnotes

The authors declare no competing financial interests.

Author Contributions W.L. performed the experiments, collected and analyzed data and participated in manuscript writing; Y.L., F.C. and S.Y. assisted some experiments and data collections; Z.L. and W.C. conceived project; W.C. designed the study, arranged results and wrote the manuscript.

References

  1. Komaba H. [The expanding concept of CKD-MBD]. Clinical calcium 26, 1253–1260, doi: CliCa160912531260 (2016). [PubMed] [Google Scholar]
  2. Kochanek M., Said A. & Lerma E. V. Mineral metabolism in chronic kidney disease. Disease-a-month: DM 61, 425–433, doi: 10.1016/j.disamonth.2015.08.003 (2015). [DOI] [PubMed] [Google Scholar]
  3. Iwashita Y., Iwashita Y., Ito T. & Shigematsu T. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)]. Clinical calcium 26, 259–267, doi: CliCa1602259267 (2016). [PubMed] [Google Scholar]
  4. Hu M.-C., Kuro-o M. & Moe O. W. Klotho and kidney disease. Journal of nephrology 23, S136 (2010). [PMC free article] [PubMed] [Google Scholar]
  5. Hu M. C., Kuro-o M. & Moe O. W. Klotho and chronic kidney disease. Contributions to nephrology 180, 47–63, doi: 10.1159/000346778 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kurosu H. et al. Suppression of aging in mice by the hormone Klotho. Science 309, 1829–1833, doi: 10.1126/science.1112766 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Olauson H. & Larsson T. E. FGF23 and Klotho in chronic kidney disease. Curr Opin Nephrol Hypertens 22, 397–404, doi: 10.1097/MNH.0b013e32836213ee (2013). [DOI] [PubMed] [Google Scholar]
  8. Kawaguchi H. et al. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. Journal of Clinical Investigation 104, 229 (1999). [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Sasaki M. et al. Altered distribution of bone matrix proteins and defective bone mineralization in klotho-deficient mice. Bone 57, 206–219, doi: 10.1016/j.bone.2013.08.008 (2013). [DOI] [PubMed] [Google Scholar]
  10. Urakawa I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774, doi: 10.1038/nature05315 (2006). [DOI] [PubMed] [Google Scholar]
  11. Dermaku-Sopjani M. et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology 28, 251–258, doi: 10.1159/000331737 (2011). [DOI] [PubMed] [Google Scholar]
  12. Xu Y. & Sun Z. Molecular basis of Klotho: from gene to function in aging. Endocrine reviews 36, 174–193, doi: 10.1210/er.2013-1079 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Doi S. et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286, 8655–8665, doi: 10.1074/jbc.M110.174037 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koh N. et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochemical and biophysical research communications 280, 1015–1020, doi: 10.1006/bbrc.2000.4226 (2001). [DOI] [PubMed] [Google Scholar]
  15. Sakan H. et al. Reduced Renal alpha-Klotho Expression in CKD Patients and Its Effect on Renal Phosphate Handling and Vitamin D Metabolism. PLoS One 9, e86301, doi: 10.1371/journal.pone.0086301 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mitani H. et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 39, 838–843 (2002). [DOI] [PubMed] [Google Scholar]
  17. Haruna Y. et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proceedings of the National Academy of Sciences of the United States of America 104, 2331–2336, doi: 10.1073/pnas.0611079104 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Zhao Y. et al. Mammalian target of rapamycin signaling inhibition ameliorates vascular calcification via Klotho upregulation. Kidney international 88, 711–721 (2015). [DOI] [PubMed] [Google Scholar]
  19. Azuma M. et al. Promoter methylation confers kidney-specific expression of the Klotho gene. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 26, 4264–4274, doi: 10.1096/fj.12-211631 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Moreno J. A. et al. The Inflammatory Cytokines TWEAK and TNF Reduce Renal Klotho Expression through NF B. Journal of the American Society of Nephrology 22, 1315–1325, doi: 10.1681/asn.2010101073 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Norris K. L., Lee J. Y. & Yao T. P. Acetylation goes global: the emergence of acetylation biology. Science signaling 2, pe76, doi: 10.1126/scisignal.297pe76 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Chen L., Fischle W., Verdin E. & Greene W. C. Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293, 1653–1657, doi: 10.1126/science.1062374 (2001). [DOI] [PubMed] [Google Scholar]
  23. Gu W. & Roeder R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90, 595–606 (1997). [DOI] [PubMed] [Google Scholar]
  24. Spange S., Wagner T., Heinzel T. & Kramer O. H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. The international journal of biochemistry & cell biology 41, 185–198, doi: 10.1016/j.biocel.2008.08.027 (2009). [DOI] [PubMed] [Google Scholar]
  25. Liu N. & Zhuang S. Treatment of chronic kidney diseases with histone deacetylase inhibitors. Frontiers in physiology 6, 121, doi: 10.3389/fphys.2015.00121 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Liu R. et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63, 2440–2453 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kinugasa F. et al. Prevention of renal interstitial fibrosis via histone deacetylase inhibition in rats with unilateral ureteral obstruction. Transplant immunology 23, 18–23 (2010). [DOI] [PubMed] [Google Scholar]
  28. Pang M. et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. American Journal of Physiology-Renal Physiology 297, F996–F1005 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Mishra N., Reilly C. M., Brown D. R., Ruiz P. & Gilkeson G. S. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. The Journal of clinical investigation 111, 539–552, doi: 10.1172/jci16153 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Dussaule J.-C. et al. Elevated Klotho Promoter Methylation Is Associated with Severity of Chronic Kidney Disease. PLoS ONE 8, e79856, doi: 10.1371/journal.pone.0079856 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sun C. Y., Chang S. C. & Wu M. S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney international 81, 640–650, doi: 10.1038/ki.2011.445 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Yokozawa T., Zheng P. D., Oura H. & Koizumi F. Animal model of adenine-induced chronic renal failure in rats. Nephron 44, 230–234 (1986). [DOI] [PubMed] [Google Scholar]
  33. Zhang Q. et al. Rhein reverses Klotho repression via promoter demethylation and protects against kidney and bone injuries in mice with chronic kidney disease. Kidney International 91, 144–156, doi: 10.1016/j.kint.2016.07.040 (2017). [DOI] [PubMed] [Google Scholar]
  34. Tamagaki K. et al. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association 21, 651–659, doi: 10.1093/ndt/gfi273 (2006). [DOI] [PubMed] [Google Scholar]
  35. Ali B. H. et al. New model for adenine-induced chronic renal failure in mice, and the effect of gum acacia treatment thereon: comparison with rats. Journal of pharmacological and toxicological methods 68, 384–393 (2013). [DOI] [PubMed] [Google Scholar]
  36. Jia T. et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC nephrology 14, 116, doi: 10.1186/1471-2369-14-116 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ferrari G. O. et al. Mineral bone disorder in chronic kidney disease: head-to-head comparison of the 5/6 nephrectomy and adenine models. BMC nephrology 15, doi: 10.1186/1471-2369-15-69 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Moe S. M. et al. The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research 26, 2672–2681, doi: 10.1002/jbmr.485 (2011). [DOI] [PubMed] [Google Scholar]
  39. Noh H. et al. Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-β1-induced renal injury. American Journal of Physiology-Renal Physiology 297, F729–F739 (2009). [DOI] [PubMed] [Google Scholar]
  40. Wang X. et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy. Kidney International 86, 712–725, doi: 10.1038/ki.2014.111 (2014). [DOI] [PubMed] [Google Scholar]
  41. Cao Y. et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models. Proceedings of the National Academy of Sciences 106, 21819–21824 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Cebotaru L. et al. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney International 90, 90–99, doi: 10.1016/j.kint.2016.01.026 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Liu F., Wu S., Ren H. & Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nature cell biology 13, 254–262 (2011). [DOI] [PubMed] [Google Scholar]
  44. Maltese G. et al. The anti-ageing hormone klotho induces Nrf2-mediated antioxidant defences in human aortic smooth muscle cells. Journal of Cellular and Molecular Medicine doi: 10.1111/jcmm.12996 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Marumo T., Hishikawa K., Yoshikawa M. & Fujita T. Epigenetic regulation of BMP7 in the regenerative response to ischemia. Journal of the American Society of Nephrology: JASN 19, 1311–1320, doi: 10.1681/asn.2007091040 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Wei K., Yin Z. & Xie Y. Roles of the kidney in the formation, remodeling and repair of bone. Journal of Nephrology 29, 349–357, doi: 10.1007/s40620-016-0284-7 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Wang S. et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy11Professor Robert Chevalier served as a guest editor for this paper. Kidney International 63, 2037–2049, doi: 10.1046/j.1523-1755.2003.00035.x (2003). [DOI] [PubMed] [Google Scholar]
  48. Schroeder T. M. & Westendorf J. J. Histone Deacetylase Inhibitors Promote Osteoblast Maturation. Journal of Bone and Mineral Research 20, 2254–2263, doi: 10.1359/jbmr.050813 (2005). [DOI] [PubMed] [Google Scholar]
  49. Rahman M. M. Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood 101, 3451–3459, doi: 10.1182/blood-2002-08-2622 (2003). [DOI] [PubMed] [Google Scholar]
  50. Ghayor C. & Weber F. Epigenetic Regulation of Bone Remodeling and Its Impacts in Osteoporosis. International Journal of Molecular Sciences 17, 1446, doi: 10.3390/ijms17091446 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Rhee Y. et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636–643, doi: 10.1016/j.bone.2011.06.025 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Raimann A. et al. Fibroblast Growth Factor 23 and Klotho Are Present in the Growth Plate. Connective Tissue Research 54, 108–117, doi: 10.3109/03008207.2012.753879 (2013). [DOI] [PubMed] [Google Scholar]
  53. Lindberg K. et al. The Kidney Is the Principal Organ Mediating Klotho Effects. Journal of the American Society of Nephrology: JASN doi: 10.1681/ASN.2013111209 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sun C.-Y., Chang S.-C. & Wu M.-S. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney International 81, 640–650, doi: 10.1038/ki.2011.445 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. la Rosa A. H., Acker M., Swain S. & Manoharan M. The role of epigenetics in kidney malignancies. Central European journal of urology 68, 157–164, doi: 10.5173/ceju.2015.453 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Hamidi T., Singh A. K. & Chen T. Genetic alterations of DNA methylation machinery in human diseases. Epigenomics 7, 247–265, doi: 10.2217/epi.14.80 (2015). [DOI] [PubMed] [Google Scholar]
  57. Wing M. R., Ramezani A., Gill H. S., Devaney J. M. & Raj D. S. Epigenetics of progression of chronic kidney disease: fact or fantasy? Seminars in nephrology 33, 363–374, doi: 10.1016/j.semnephrol.2013.05.008 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Zhang H. et al. Klotho is a target gene of PPAR-gamma. Kidney international 74, 732–739, doi: 10.1038/ki.2008.244 (2008). [DOI] [PubMed] [Google Scholar]
  59. Chihara Y. et al. Klotho protein promotes adipocyte differentiation. Endocrinology 147, 3835–3842, doi: 10.1210/en.2005-1529 (2006). [DOI] [PubMed] [Google Scholar]
  60. Qin T. et al. Sinomenine activation of Nrf2 signaling prevents hyperactive inflammation and kidney injury in a mouse model of obstructive nephropathy. Free radical biology & medicine 92, 90–99, doi: 10.1016/j.freeradbiomed.2016.01.011 (2016). [DOI] [PubMed] [Google Scholar]
  61. Liu L., Lin W., Zhang Q., Cao W. & Liu Z. TGF-β induces miR-30d down-regulation and podocyte injury through Smad2/3 and HDAC3-associated transcriptional repression. Journal of Molecular Medicine 94, 291–300, doi: 10.1007/s00109-015-1340-9 (2016). [DOI] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES